Chen Hongbo, Zhang Xiaohong, Li Jiaying, Xu Zhe, Luo Yiwei, Chai Rundong, Luo Ruzhen, Bian Yuhong, Liu Yanhui
School of Nursing, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin 301617, P. R. China.
School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin 301617, P. R. China.
ACS Omega. 2023 Jul 24;8(30):26871-26881. doi: 10.1021/acsomega.3c01489. eCollection 2023 Aug 1.
Infections and death have been a part of our daily lives since the COVID-2019 pandemic outbreak in 2019, and the societal and economic consequences have lingered for an unanticipated duration. Novel and effective treatments are still desperately needed around the world to combat the infection. Here, we discovered a novel traditional Chinese medicine formula (TCMF) to potentially combat COVID-19 through reverse systematic pharmacology (disease → targets → TCMF → disease).
Combining Integrative network pharmacology and the traditional Chinese medicine (TCM) theory, a TCMF for COVID-19 was identified. physiological interactions between herbs and disease hub targets were validated by molecular docking and dynamics simulation.
Based on disease-related gene/pathway targets and a combination of reverse pharmacology and TCM meridian tropism theory, a COVID-19-associated herb database was constructed. A new TCMF, including Gancao, Baitouweng, Congbai, and Diyu (GBCD), was discovered for anti-COVID-19 therapy. The KEGG and GO analyses of 49 intersecting genes suggested that GBCD could combat COVID-19 through antiviral, antiinflammation, immunoregulation, and cytoprotection activities. Moreover, these possible effects were validated through docking and MD simulation.
To the best of our knowledge, this study is the first to combine reverse pharmacology and meridian tropism theories for TCMF development, and a novel herbal combination, GBCD, was discovered for anti-COVID-19 therapy.
自2019年新冠疫情爆发以来,感染和死亡一直是我们日常生活的一部分,其社会和经济影响持续了一段意想不到的时间。世界各地仍迫切需要新的有效治疗方法来对抗这种感染。在此,我们通过反向系统药理学(疾病→靶点→中药方剂→疾病)发现了一种新型中药方剂,有望对抗新冠病毒。
结合整合网络药理学和中医理论,确定了一种用于治疗新冠的中药方剂。通过分子对接和动力学模拟验证了草药与疾病核心靶点之间的生理相互作用。
基于疾病相关基因/通路靶点,结合反向药理学和中医经络归经理论,构建了一个与新冠相关的草药数据库。发现了一种新的中药方剂,包括甘草、白头翁、葱白和地榆(GBCD),用于抗新冠治疗。对49个交集基因的KEGG和GO分析表明,GBCD可通过抗病毒、抗炎、免疫调节和细胞保护活性来对抗新冠。此外,通过对接和分子动力学模拟验证了这些可能的作用。
据我们所知,本研究首次将反向药理学和经络归经理论结合用于中药方剂开发,并发现了一种新型草药组合GBCD用于抗新冠治疗。